From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers
Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders …

Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for
patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer …

Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant.
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free
factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable …

Background: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of
activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …